PREVIOUS
✖
Bharat Biotech’s intranasal Covid vaccine
December 2 , 2022
727 days
778
0
- Bharat Biotech’s iNCOVACC has become the world’s first intranasal Covid-19 vaccine to receive emergency use authorisation.
- It can be used as a primary vaccine as well as heterologous booster for those who have received two doses of another vaccine.
- iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilized SARS-CoV-2 spike protein.
Leave a Reply
Your Comment is awaiting moderation.